The Stem Cell Therapeutic and Research Reauthorization Act of 2025 (H.R. 5160) aims to continue and enhance federal support for programs that provide life-saving stem cell treatments. Specifically, it proposes to:
- Reauthorize the C.W. Bill Young Cell Transplantation Program, which facilitates bone marrow and cord blood transplants for patients with conditions like leukemia and lymphoma, with an annual funding of $33 million from fiscal years 2027 through 2031.
- Extend the National Cord Blood Inventory program, ensuring its operation through 2031, to maintain and expand the collection of cord blood units used in transplants.
This legislation seeks to ensure the ongoing availability and advancement of stem cell therapies for patients in need.
Media coverage has highlighted the bipartisan support for H.R. 5160, emphasizing its role in sustaining critical programs that offer life-saving treatments. For instance, a press release from Congressman Gus Bilirakis notes that the bill would reauthorize over $280 million over five years for national cord blood and bone marrow transplant programs, underscoring the legislation's importance in providing essential medical services to patients with serious diseases. [Source: Congressman Gus Bilirakis Press Release](https://bilirakis.house.gov/media/press-releases/bipartisan-bill-introduced-reauthorize-national-cord-blood-and-bone-marrow)
As of now, there is limited media coverage expressing opposition to H.R. 5160. However, potential concerns could arise regarding the allocation of federal funds, with critics possibly questioning whether the increased funding for these programs is the most effective use of resources, especially in the context of other pressing healthcare needs. Additionally, debates may emerge over the ethical considerations of stem cell research, although this bill focuses on reauthorizing existing programs rather than introducing new research initiatives.
The sponsorship of H.R. 5160 by Christopher Smith raises potential conflicts of interest due to significant financial contributions from the health professionals sector, totaling $120 million. This sector is directly related to the subject matter of the bill, which focuses on stem cell therapeutic research and reauthorization. The alignment of the sponsor's top donor industry with the bill's focus suggests a potential bias towards legislation that may favor the interests of these donors. Furthermore, while the total donations from the health professionals sector are substantial, the absence of PAC contributions indicates that these funds come from individual donors, which may complicate the perception of influence. Voters should be aware that the financial interests of health professionals could shape the legislative agenda in ways that may not align with broader public health interests.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $120,000,000 |
| Total from overlapping industries | $120,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| DIRSHU INTERNATIONAL | MERKAVA STRATEGIES CORPORATION | $100,000 |
| CEO WORKS | SAUNDERS GLOBAL DIPLOMACY | $45,000 |
| KAZI IG | SAUNDERS GLOBAL DIPLOMACY | $15,000 |
| KEY LARGO WASTEWATER TREATMENT DISTRICT | HICKS-RICHARDSON ASSOCIATES | $10,000 |
| WATERFRONT GLOBAL | BBT STRATEGIES LLC | $5,200 |
| DIGITALEUROPE | VIVID STRATEGIES LLC | undisclosed |
| INTERNATIONAL CHRISTIAN CHAMBER OF COMMERCE | MERKAVA STRATEGIES CORPORATION | undisclosed |
| DR. STEPHEN SOLOWAY | MERKAVA STRATEGIES CORPORATION | undisclosed |
| ONE ISRAEL FUND | MERKAVA STRATEGIES CORPORATION | undisclosed |
| HEMOGLOBIN OXYGEN THERAPEUTICS | MERKAVA STRATEGIES CORPORATION | undisclosed |
| ATAOLLAH AMINPOUR | MERKAVA STRATEGIES CORPORATION | undisclosed |
| HERSEL NEMAN | MERKAVA STRATEGIES CORPORATION | undisclosed |
| MORAD BEN NEMAN | MERKAVA STRATEGIES CORPORATION | undisclosed |
| MARK SCOTT | MERKAVA STRATEGIES CORPORATION | undisclosed |
| BORIS MINTS | MERKAVA STRATEGIES CORPORATION | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Christopher Smith, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
